This Ciena Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage: Buy on FORM ($200), NUVB ($12); Outperform on CIEN ($440); Neutral on EXPD ($180); Equal-Weight on SFD ($22).
Stocks · News reference
Nuvation Bio Says FDA Approves sNDA For IBTROZI, ROS1 Inhibitor For Treatment Of Locally Advanced Or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 monthsNo changes to the safety sections of labeling with longer follow-up and no new safety signals identifiedApproval comes four months
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12
Citigroup analyst Geoff Meacham initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy rating and announces Price Target of $12.
Nuvation Bio shares are trading higher after the company announced the FDA approval of its sNDA for IBTROZI with updated duration of response in TKI-naïve advanced ROS1-positive non-small cell lung cancer.
Why Is Nuvation Bio Stock Gaining Thursday?
Nuvation Bio (NUVB) stock jumps 6% after early FDA label update for IBTROZI, highlighting over 4 years of clinical benefit in ROS1+ NSCLC.